Business & Finance
Exicure incurs higher net loss of USD23.5m for Q3 2021
22 November 2021 -

Immunotherapeutic drugs company Exicure Inc (NASDAQ:XCUR) stated on Friday its net loss of USD23.5m for the third quarter ended 30 September 2021.

This marks a decline in earnings when compared with a net loss of USD8.8m for the third quarter ended 30 September 2020. The increase in net loss was primarily driven by higher R&D costs to advance its pipeline, as well as lower non-cash revenue during the period largely impacted by the reversal of non-cash revenue associated with its collaboration with AbbVie Inc.

Total revenues of USD3.68m were generated for the third quarter ended 30 September 2021, a growth from USD2.44m for the third quarter ended 30 September 2020.

R&D expenses of USD16.5m were recorded for the third quarter ended 30 September 2021, a rise over R&D of USD9.1m for the quarter ended 30 September 2020, reflecting increased headcount, related increase in R&D activities and increased clinical trial activities.

Login
Username:

Password: